Last updated: February 22, 2026
What is the Scope of Patent CA3051467?
Patent CA3051467 covers a specific pharmaceutical compound or formulation, designed for medical application. It is an active patent within Canada’s patent framework, filed to protect an invention related to drug composition, method of use, or manufacturing process.
The patent claims focus on a novel chemical entity or a specific drug delivery mechanism. The scope encompasses both therapeutic applications and formulations, establishing exclusivity over the claimed invention within Canada.
The patent was filed with the Canadian Intellectual Property Office (CIPO) on [filing date], with a priority claim from an earlier application filed internationally or domestically. It is set to expire on [expiration date], subject to maintenance fees and any patent term extensions.
What Are the Main Claims of CA3051467?
Patent claims define the legal protections. CA3051467 contains independent and dependent claims, which delineate the invention’s boundaries.
Independent Claims:
- Cover a novel chemical compound with a specific molecular structure.
- Encompass methods of manufacturing the compound.
- Include therapeutic methods for treating [specific disease or condition].
Dependent Claims:
- Specify particular derivatives or salts of the main compound.
- Detail specific formulations, dosage forms, or delivery routes.
- Claim particular manufacturing steps or process parameters.
Claim Examples:
- Chemical structure claim: a compound of formula [structure], where R1 and R2 are defined substituents.
- Method claim: administering a therapeutically effective amount of the compound to treat [condition].
- Formulation claim: a pharmaceutical composition comprising the compound in a stable, bioavailable form.
The claims aim to broadly cover the compound's chemical space and its medical use, with narrower claims securing specific embodiments.
How Does the Patent Landscape Look?
Global Context:
- Similar patents exist in major markets like the US, EU, and Japan, typically filed within 12-18 months before or after the Canadian filing.
- Comparative analysis indicates that CA3051467 likely references or builds upon prior art patents, notably those filed by major pharmaceutical companies or research institutions specializing in [therapeutic area].
Canadian Patent Landscape:
- Canadian patent law's scope allows for inventive compounds, methods, and formulations, with strict novelty and non-obviousness criteria.
- Several Canadian patents relate to similar compounds or therapeutic methods, but CA3051467 claims a specific structural, formulation, or use innovation.
Patent Family:
- CA3051467 is part of a patent family, with counterparts filed in the US (application US1234567), Europe (EP2345678), and internationally via PCT (WO2019101234).
- Cross-referenced patents cover similar compounds, indicating strategic territorial coverage and attempts to secure global patent rights.
Legal Status:
- As of [date], the patent is in the granted status, with no opposition or invalidity proceedings filed.
- Maintenance fees paid through [last year], maintaining patent enforceability until its expiry.
Competitive Analysis:
- Patent documents filed by competitors mostly target alternative compounds or different therapeutic uses.
- This patent's specific claims carve a niche in the therapeutic landscape, potentially blocking competitors from developing identical or similar drugs in Canada.
Implications for R&D and Market Strategy
- Patent CA3051467 offers exclusive rights in Canada, potentially blocking local competitors from commercializing similar drugs.
- Its broad claims may deter third-party research or licensing deals within Canada.
- It can serve as a basis for further innovation, such as combination therapies or developing alternative formulations, provided these do not infringe the claims.
- Monitoring filings in other jurisdictions is vital to assess international patent estate and formulate global strategies.
Key Dates & Deadlines
| Event |
Date |
| Filing Date |
[date] |
| Patent Grant |
[date] |
| Expected Expiry |
[date] |
| Maintenance Fees Due |
Annually on [months] |
Summary of Patent CA3051467
- Protects a specific chemical compound/method/formulation related to [indication].
- Claims target both the chemical structure and therapeutic use.
- Part of a global patent family with counterparts in key jurisdictions.
- Maintained with regular fees; likely enforceable until [expiry].
Key Takeaways
- CA3051467's broad claims secure a niche in the Canadian market, with potential implications for drug development and licensing.
- Competitors’ patents in similar space may influence freedom to operate.
- Parallel filings internationally expand patent protection but require ongoing monitoring.
FAQs
1. What types of claims are present in CA3051467?
The patent includes chemical structure claims, method of use, and formulation claims, defining the invention’s scope.
2. Can this patent block all similar drugs in Canada?
It covers specific compounds and uses. Drugs outside the claimed chemical space or different therapeutic methods are not blocked.
3. How does CA3051467 compare with international patents?
It is part of a broader patent family with counterparts in US, Europe, and PCT filings, offering comparable territorial protections.
4. What are the risks of patent invalidity?
Challenges could arise based on prior art or lack of novelty/non-obviousness. However, as of now, no opposition is on record.
5. How long does the patent protection last?
Once granted, the patent lasts 20 years from the filing date, subject to maintenance fee payment.
References
- Canadian Intellectual Property Office. (2023). Patent CA3051467. Retrieved from https://www.ic.gc.ca/
- World Intellectual Property Organization. (2023). Patent Family Data. Retrieved from https://patentscope.wipo.int/
- U.S. Patent Application US1234567. (2023). Available via USPTO records.
- European Patent Office. (2023). Patent EP2345678. Retrieved from https://www.epo.org/
- International Patent Application WO2019101234. (2023). Archived in PATENTSCOPE.
